{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:48:44Z","timestamp":1794930524024,"version":"4.9.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["NCT03574597"],"award-info":[{"award-number":["NCT03574597"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>In SELECT, subcutaneous semaglutide (target dose 2.4 mg) weekly in adults with pre-existing cardiovascular disease and body mass index \u226527\u2005kg\/m2 without diabetes significantly reduced major adverse cardiovascular events (MACE) by 20% vs placebo. This analysis explored potential mediators of this cardiovascular benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Changes from randomization to 24 months in body weight, waist circumference, plasma high-sensitivity C-reactive protein (hsCRP), glycated haemoglobin (HbA1c), lipids, blood pressure, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio were examined individually, and in combination, as potential mediators of MACE risk reduction, using the Vansteelandt repeated regression method (a counterfactual approach).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Semaglutide significantly (P &amp;lt; .05) improved all potential mediators investigated. Point estimates for % mediation were largest for waist circumference (64.0% [95% confidence interval (CI) 27.5, 179.6]), hsCRP (42.1% [17.9, 110.5]), HbA1c (29.0% [\u221220.7, 120.5]), and body weight (19.5% [\u221233.0, 110.7]), examined separately, but all had wide CIs. Supplementary analyses suggested unreliability of estimates for body weight and waist circumference, potentially due to differing relationship of body weight and waist change to MACE between treatment arms. Multivariable analysis estimated joint mediation for all potential mediators combined to be 31.4% (95% CI \u221230.1, 143.6). When variables other than body weight and waist circumference were considered, % mediation was 46.0% (95% CI \u22126.0, 161.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mediation analyses could not fully ascribe the effects of semaglutide on MACE to known risk factors in SELECT with any certainty. Further investigation of potential additional biomarkers and mediators of semaglutide's cardiovascular protective effect are of interest.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag524","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:38:19Z","timestamp":1782214699000},"source":"Crossref","is-referenced-by-count":5,"title":["Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-3288","authenticated-orcid":false,"given":"Helen M","family":"Colhoun","sequence":"first","affiliation":[{"name":"Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh EH4 2XU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-2277","authenticated-orcid":false,"given":"Donna","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pennington Biomedical Research Center , Baton Rouge, LA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-7401","authenticated-orcid":false,"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Endocrinology and Peter O\u2019Donnel Jr School of Public Health, UT Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Kahn","sequence":"additional","affiliation":[{"name":"Department of Medicine, VA Puget Sound Health Care System and University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Hardt-Lindberg","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugce Kalayci","family":"Oral","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E","family":"Weeke","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Linder","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-7850","authenticated-orcid":false,"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartolome","family":"Burguera","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Institute, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 P","family":"van Beek","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-8862","authenticated-orcid":false,"given":"Jose Francisco Kerr","family":"Saraiva","sequence":"additional","affiliation":[{"name":"Clinical Research Institute of Campinas , Sao Paolo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Arbel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tel Aviv Sourasky University Medical Center (Ichilov), affiliated with the Faculty of Medical & Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott S","family":"Emerson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Deanfield","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092318063062700_ehag524-B1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026092318063062700_ehag524-B2","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1093\/eurheartj\/ehad445","article-title":"Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table","volume":"44","author":"Cosentino","year":"2023","journal-title":"Eur Heart J"},{"key":"2026092318063062700_ehag524-B3","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24314","article-title":"Glucagon-like peptide-1 receptor agonists and major adverse cardiovascular events in patients with and without diabetes: a meta-analysis of randomized-controlled trials","volume":"47","author":"Hosseinpour","year":"2024","journal-title":"Clin Cardiol"},{"key":"2026092318063062700_ehag524-B4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"GLP-1 receptor agonists and cardiovascular outcome trials: an update","volume":"60","author":"Andrikou","year":"2019","journal-title":"Hellenic J Cardiol"},{"key":"2026092318063062700_ehag524-B5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026092318063062700_ehag524-B6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/s2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026092318063062700_ehag524-B7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"2026092318063062700_ehag524-B8","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.2337\/dc19-2251","article-title":"Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"2026092318063062700_ehag524-B9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12933-021-01386-4","article-title":"Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND","volume":"20","author":"Konig","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026092318063062700_ehag524-B10","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/s0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"2026092318063062700_ehag524-B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"2026092318063062700_ehag524-B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"2026092318063062700_ehag524-B13","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1002\/sim.8336","article-title":"Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding","volume":"38","author":"Vansteelandt","year":"2019","journal-title":"Stat Med"},{"key":"2026092318063062700_ehag524-B14","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/ndt\/gfae032","article-title":"How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial","volume":"39","author":"Wanner","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026092318063062700_ehag524-B15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.molimm.2022.04.003","article-title":"IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms","volume":"146","author":"Ngwa","year":"2022","journal-title":"Mol Immunol"},{"key":"2026092318063062700_ehag524-B16","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1001\/jama.282.22.2131","article-title":"Elevated C-reactive protein levels in overweight and obese adults","volume":"282","author":"Visser","year":"1999","journal-title":"JAMA"},{"key":"2026092318063062700_ehag524-B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102388","article-title":"Effect of calorie restriction diet on levels of C reactive protein (CRP) in obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Kemalasari","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"2026092318063062700_ehag524-B18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2026092318063062700_ehag524-B19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.2337\/dc23-0231","article-title":"Dulaglutide and kidney function\u2013related outcomes in type 2 diabetes: a REWIND post hoc analysis","volume":"46","author":"Botros","year":"2023","journal-title":"Diabetes Care"},{"key":"2026092318063062700_ehag524-B20","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","volume":"46","author":"Mahaffey","year":"2025","journal-title":"Eur Heart J"},{"key":"2026092318063062700_ehag524-B21","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026092318063062700_ehag524-B22","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2026092318063062700_ehag524-B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-023-02096-9","article-title":"Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network","volume":"23","author":"Garc\u00eda-Vega","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026092318063062700_ehag524-B24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41591-024-03355-2","article-title":"Proteomic changes upon treatment with semaglutide in individuals with obesity","volume":"31","author":"Maretty","year":"2025","journal-title":"Nat Med"},{"key":"2026092318063062700_ehag524-B25","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","article-title":"The effect of semaglutide on mortality and COVID-19-related deaths: an analysis from the SELECT trial","volume":"84","author":"Scirica","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag524\/70852550\/ehag524.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag524\/70852550\/ehag524.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:06:40Z","timestamp":1790201200000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag524\/8774585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag524","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"ehag524"}}